Severe Asthma Pipeline Assessment, 2024: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Severe Asthma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.

The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Severe Asthma Pipeline Report: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years.
• Severe Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others, are developing therapies for the Severe Asthma treatment
• Emerging Severe Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others are expected to have a significant impact on the Severe Asthma market in the coming years.
• In February 2022, In order to treat asthma and chronic obstructive pulmonary disease (COPD), Honeywell and AstraZeneca have formed a business agreement to create and sell next-generation respiratory inhalers that use propellants with almost no global warming potential (GWP).
• In March 2021, GlaxoSmithKline initiated a trial titled, "A 52-week, Randomized, Double-blind, Placebo controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants with Severe Uncontrolled Asthma with an Eosinophilic Phenotype".

Severe Asthma Overview
The chronic lung disease known as asthma causes the airways to become inflamed and hyperactive. Asthma has a wide range of signs and symptoms that can be brought on by breathing in environmental allergens including pollen, dust, animal dander, mould, or other irritants. When someone is diagnosed with severe asthma, they need to take other longer-acting drugs along with medium- or high-dose inhaled corticosteroids.

Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight

Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:
• LNR 125.38: Lanier Biotherapeutics
• BAT2606: Bio-Thera Solutions
• KN-002: Kinaset Therapeutics
• CM326: CSPC ZhongQi Pharmaceutical Technology
• FB 704A: Oneness Biotech Co., Ltd.
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• Masitinib: AB Science
• GSK3511294: GlaxoSmithKline
Severe Asthma Pipeline Therapeutics Assessment
• Severe Asthma Assessment by Product Type
• Severe Asthma By Stage and Product Type
• Severe Asthma Assessment by Route of Administration
• Severe Asthma By Stage and Route of Administration
• Severe Asthma Assessment by Molecule Type
• Severe Asthma by Stage and Molecule Type

DelveInsight's Severe Asthma Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Severe Asthma Therapeutics Market include:
Key companies developing therapies for Severe Asthma are - Genentech, Inc., GlaxoSmithKline, Kymab, Sanofi, 4D Pharma plc, AstraZeneca, Sinomab, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Cumberland Pharmaceuticals, and others.

Severe Asthma Pipeline Analysis:
The Severe Asthma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.
• Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Severe Asthma drugs and therapies
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Asthma Pipeline Market Drivers
• Increase in the prevalence of Severe Asthma, development of new and innovative treatment options for severe asthma are some of the important factors that are fueling the Severe Asthma Market.
Severe Asthma Pipeline Market Barriers
• However, high cost of asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Severe Asthma Market growth.
Scope of Severe Asthma Pipeline Drug Insight
• Coverage: Global
• Key Severe Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others
• Key Severe Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others
• Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
• Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers
Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Severe Asthma Report Introduction
2. Severe Asthma Executive Summary
3. Severe Asthma Overview
4. Severe Asthma- Analytical Perspective In-depth Commercial Assessment
5. Severe Asthma Pipeline Therapeutics
6. Severe Asthma Late Stage Products (Phase II/III)
7. Severe Asthma Mid Stage Products (Phase II)
8. Severe Asthma Early Stage Products (Phase I)
9. Severe Asthma Preclinical Stage Products
10. Severe Asthma Therapeutics Assessment
11. Severe Asthma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Severe Asthma Key Companies
14. Severe Asthma Key Products
15. Severe Asthma Unmet Needs
16 . Severe Asthma Market Drivers and Barriers
17. Severe Asthma Future Perspectives and Conclusion
18. Severe Asthma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Severe Asthma Market https://www.delveinsight.com/report-store/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Severe Asthma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Severe Asthma Epidemiology https://www.delveinsight.com/report-store/severe-asthma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Severe Asthma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.